Richard Mortimer - The Competitive Landscape for Biosimilars
January 0001
While intellectual property and antitrust litigation involving pharmaceuticals has long been widespread in the US, the recent emergence of biosimilar drugs has raised a number of questions around how this litigation will evolve.